Revisiting the Indication for Prophylactic Contralateral Mastectomy in Patients with Li-Fraumeni Syndrome and Breast Cancer. Case Report

Overview

Journal Rev Colomb Obstet Ginecol

Specialty Gynecology & Obstetrics

Date 2021 Dec 1

PMID 34851573

Authors

Ximena Briceno-Morales

Clara Briceno-Morales

Silvia Ines Guerrero-Macias

Ana Maria Pedroza-Duran

Raul Alexis Suarez-Rodriguez

Affiliations

Soon will be listed here.

Abstract

Objective: To describe the case of a patient with Li-Fraumeni syndrome (LFS) and breast cancer in whom the benefit of contralateral prophylactic mastectomy (CPM) was challenged; and to offer a critical discussion regarding the evidence supporting this procedure in this patient population.

Case Presentation: A 37-year-old woman with breast cancer and a family history of multiple early onset cancer of the LFS spectrum in whom a pathogenic variant of the TP53 gene was confirmed during adjuvant hormonal therapy. The case was presented during the multidisciplinary meeting of the Breast Service of a referral oncology center in Colombia, in order to discuss the benefit of CPM. The decision of the board meeting was not to perform CPM. After 30 months of follow-up, the patient is disease-free.

Conclusion: There is no evidence on the impact of CPM on survival of patients with LFS and breast cancer in particular. However, in light of the current knowledge, it is not possible to generalize the approach of withholding this prophylactic surgery. It is important to report those cases in which the decision is made to either perform or omit this procedure in order to increase the body of evidence, considering the limitations that make it difficult to build large cohorts or conduct trials exclusively for this genetic disorder.

References

Kwong A, Shin V, Ho C, Au C, Slavin T, Weitzel J . Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer. 2020; 20(1):1053. PMC: 7607817. DOI: 10.1186/s12885-020-07476-y. View

Hwang S, Lozano G, Amos C, Strong L . Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003; 72(4):975-83. PMC: 1180359. DOI: 10.1086/374567. View

Evans D, Ingham S, Baildam A, Ross G, Lalloo F, Buchan I . Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013; 140(1):135-42. DOI: 10.1007/s10549-013-2583-1. View

Waks A, Winer E . Breast Cancer Treatment: A Review. JAMA. 2019; 321(3):288-300. DOI: 10.1001/jama.2018.19323. View

Biglia N, DAlonzo M, Sgro L, Tomasi Cont N, Bounous V, Robba E . Breast cancer treatment in mutation carriers: surgical treatment. Minerva Ginecol. 2016; 68(5):548-56. View

Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B . Inherited p53 gene mutations in breast cancer. Cancer Res. 1992; 52(10):2984-6. View

van der Groep P, van der Wall E, van Diest P . Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011; 34(2):71-88. PMC: 3063560. DOI: 10.1007/s13402-011-0010-3. View

Malkin D, Li F, Strong L, Fraumeni Jr J, Nelson C, Kim D . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-8. DOI: 10.1126/science.1978757. View

Kuba M, Lester S, Bowman T, Stokes S, Taneja K, Garber J . Histopathologic features of breast cancer in Li-Fraumeni syndrome. Mod Pathol. 2020; 34(3):542-548. DOI: 10.1038/s41379-020-0610-4. View

10.

Mai P, Best A, Peters J, DeCastro R, Khincha P, Loud J . Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016; 122(23):3673-3681. PMC: 5115949. DOI: 10.1002/cncr.30248. View

11.

Silva A, Lapin B, Yao K, Song D, Sisco M . The Effect of Contralateral Prophylactic Mastectomy on Perioperative Complications in Women Undergoing Immediate Breast Reconstruction: A NSQIP Analysis. Ann Surg Oncol. 2015; 22(11):3474-80. DOI: 10.1245/s10434-015-4628-7. View

12.

Levine D, Gemignani M . Prophylactic surgery in hereditary breast/ovarian cancer syndrome. Oncology (Williston Park). 2003; 17(7):932-41; discussion 946-8, 950-2. View

13.

van Sprundel T, Schmidt M, Rookus M, Brohet R, van Asperen C, Rutgers E . Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005; 93(3):287-92. PMC: 2361560. DOI: 10.1038/sj.bjc.6602703. View

14.

Liederbach E, Piro R, Hughes K, Watkin R, Wang C, Yao K . Clinicopathologic features and time interval analysis of contralateral breast cancers. Surgery. 2015; 158(3):676-85. DOI: 10.1016/j.surg.2015.03.059. View

15.

Fayanju O, Stoll C, Fowler S, Colditz G, Margenthaler J . Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg. 2014; 260(6):1000-10. PMC: 4539958. DOI: 10.1097/SLA.0000000000000769. View

16.

Valachis A, Nearchou A, Lind P . Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014; 144(3):443-55. DOI: 10.1007/s10549-014-2890-1. View

17.

Li X, You R, Wang X, Liu C, Xu Z, Zhou J . Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review. Clin Cancer Res. 2016; 22(15):3971-81. DOI: 10.1158/1078-0432.CCR-15-1465. View

18.

Gentile M, Bergman Jungestrom M, Olsen K, Soderkvist P, Wingren S . p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer. 2000; 35(8):1202-7. DOI: 10.1016/s0959-8049(99)00121-5. View

19.

Birch J, Hartley A, Tricker K, Prosser J, Condie A, Kelsey A . Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994; 54(5):1298-304. View

20.

Davis F, McCarthy B, Freels S, Kupelian V, Bondy M . The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer. 1999; 85(2):485-91. View